BDBM557620 US11358948, Compound I-29::US11623932, Compound 29

SMILES O=C1CC(CN1C1CCC(=O)NC1=O)c1ccccc1

InChI Key InChIKey=KBGHRGPBDAUOPL-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 557620   

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+3nMAssay Description:Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from the commerc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataKd: <1.00E+4nMAssay Description:Measuring compound ligand binding to CRBN-DDB1 was carried out using an established sensitive and quantitative in vitro fluorescence polarization (FP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+4nMAssay Description:Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a serial 3-fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+4nMAssay Description:Table 3: Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent